Glucosamine and Alzheimer’s risk have been connected in a new way. Researchers at the University of Florida found that people who used the popular joint supplement were more likely to see mild cognitive impairment progress into full-blown dementia.
The findings are drawn from more than 4,600 patient records plus lab experiments on mice and human brain tissue. They do not prove that glucosamine causes harm, but they raise a question millions of supplement users had never been asked.
Glucosamine and Alzheimer’s risk: what the new study found
The research team, led by Ramon Sun at the University of Florida’s McKnight Brain Institute, used artificial intelligence to comb through de-identified UF Health medical records collected between 2012 and 2024.
They focused on two groups: 2,750 patients with MCI and 1,896 patients already diagnosed with ADRD. In both groups, about 8% of patients reported taking glucosamine.
After adjusting for age, sex and other demographic factors, the team found that glucosamine use was tied to a 25% higher likelihood that MCI would progress into dementia.[1]
Among patients who already had dementia, glucosamine use was also linked to a 25% higher risk of death during the study period, though that mortality link did not appear in the MCI group.
The 8% usage rate relies on self-reported information or what appeared in medical charts. Some patients who actually took glucosamine may not have been recorded, while others classified as users may have taken it only briefly.
Glucosamine and Alzheimer’s risk: why this supplement worried researchers
Alzheimer’s disease affects roughly 7 million people in the United States alone, with millions more living with related dementias such as Lewy body or frontotemporal dementia.[2]
Glucosamine, meanwhile, is one of the most widely used over-the-counter supplements among older adults. It is taken for joint pain and joint health, and commercial versions are made from materials such as shellfish shells or corn.
"A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse," said Sun, who directs UF’s Center for Advanced Spatial Biomolecule Research.
Other everyday health choices have drawn similar scrutiny. A shingles vaccine study from Brown University linked a single shot to a 24% lower dementia risk in older adults.
How common is glucosamine, and does it even relieve joint pain?
Glucosamine has been popular among people with joint pain for decades. It is sold over the counter and is chemically similar to a natural component of cartilage, which fueled early hope that it might support joint health.
Evidence on whether glucosamine actually relieves joint pain has been mixed. Some trials reported modest benefits, while others found no meaningful difference from a placebo.
Despite that mixed record, glucosamine remains widely sold, especially among older adults. Part of what makes this new study notable is precisely that so many people have taken it for so long with little scrutiny.
Commercial glucosamine comes in two chemical forms, sulfate and hydrochloride. Whether the two forms differ in effect or safety is not well established, and this study did not distinguish between them.
How glucosamine may speed up Alzheimer’s, according to the mechanism study
To explore a possible mechanism, the team used a spatial technology developed in Sun’s lab that maps thousands of molecules created when the body breaks down food or drugs.
Glucosamine turned out to be a sugar-related molecule able to cross the blood-brain barrier, the protective boundary that tightly controls which substances move from the bloodstream into brain tissue.
Once inside the brain, glucosamine can feed into the same pathways that build sugar structures and attach them to proteins.
A healthy brain and an Alzheimer’s-affected brain may respond very differently to the same molecule, and the Alzheimer’s brain appeared especially vulnerable to this pathway.[1]
What happened in mice and human brain tissue
In genetically modified mice, glucosamine significantly increased the attachment of sugar residues to proteins inside brain cells.
Mice treated with glucosamine also developed worse deficits in social memory — memory of recognizing other individuals — compared with untreated animals.
When the researchers used a chemical treatment to block the sugar-attachment process, the mice’s memory performance improved, suggesting the excess sugar-tagging was directly involved in the memory problems rather than just a coincidence.
The team also examined human brain tissue supplied by the UF Neuromedicine Brain and Tissue Bank. Samples from people who had Alzheimer’s disease showed significantly more of this sugar attachment than tissue from people without the disease.[1]
How the analysis itself was carried out
The team used two complementary approaches: an AI-based analysis of existing medical records, and laboratory experiments in mice and human brain tissue.
The records analysis adjusted statistically for age, sex and other demographic factors to filter out differences unrelated to glucosamine use. That kind of adjustment is standard in retrospective studies, but it cannot fully control for factors that were never recorded.
In the lab, a spatial technology developed in Sun’s lab played a central role. It maps where molecules are located within tissue, rather than just measuring an average across a sample, giving a more detailed picture than older methods.
Combining the two approaches is considered a strength: a pattern found in human records was backed up by animal and tissue experiments, making pure coincidence less likely. What is still missing is the final step, a causal test in humans.
The analysis covered 12 years of records, from 2012 to 2024, but all of it came from a single health system. Whether the same pattern holds elsewhere has not yet been tested.
What this means for people taking glucosamine now
The results do not mean people should necessarily stop taking glucosamine. The health-record findings are associational, and a retrospective analysis cannot rule out other differences between supplement users and non-users.
"The electronic health record data are very provocative," said co-author Matt Gentry, chair of UF’s Department of Biochemistry and Molecular Biology.
"While it’s an association and not proof of causality, it does raise an important clinical question that now deserves much more attention," he added.
A controlled clinical trial will be needed to determine whether glucosamine actually accelerates Alzheimer’s progression, and if so, which patients face the greatest risk.
Anyone with cognitive concerns who currently takes glucosamine may want to discuss it with a doctor rather than stopping on their own, since joint pain and mobility also affect long-term health.
Outlook and the limits of the evidence
This study adds to a broader shift in Alzheimer’s research, which has long focused on amyloid plaques and tau tangles, the two hallmark abnormalities in the disease.
The new findings suggest that disrupted metabolism, including excess sugar-tagging of proteins, may be an additional driver of the disease rather than just a side effect of it.
The amyloid hypothesis has guided Alzheimer’s research for decades, but drugs based on it have often underperformed expectations, pushing more researchers toward other pathways such as metabolism or inflammation. This finding fits into that broader shift.
If a future clinical trial confirms this link, doctors may need to apply different criteria when recommending joint supplements to patients who already have cognitive impairment.
Still, the study has real limits. It covers patients from a single health system, relies on self-reported supplement use, and cannot separate correlation from causation.
Sun and his colleagues say the next step is a prospective clinical trial that follows glucosamine users forward in time to see whether the pattern holds up under more rigorous conditions.
| Aspect | Finding |
|---|---|
| Study population | 4,646 UF Health patients (2012–2024): 2,750 with MCI, 1,896 with ADRD |
| Glucosamine use | About 8% of patients in both groups reported taking it |
| MCI-to-dementia progression | 25% higher likelihood with glucosamine use |
| Mortality in ADRD group | 25% higher risk of death with glucosamine use |
| Mortality in MCI group | No significant link observed |
| Proposed mechanism | Excess hyperglycosylation (protein sugar-tagging) in the Alzheimer’s brain |
| Study design | Retrospective records plus mouse and human brain-tissue experiments, not a clinical trial |
References
- Hawkinson, T.R. et al. “Hyperglycosylation is a metabolic driver of Alzheimer’s disease.” Nature Metabolism, 2026; 8(6):1410.
- UF Health, “Glucosamine, a popular joint supplement, linked to faster Alzheimer’s progression,” ScienceDaily, September 27, 2026.
